Quick Links: Skip to main page content
Skip to Search
Skip to Topics Menu
Skip to Common Links
U.S. Food & Drug Administration
Follow FDA
En Español
Search FDA
Home
Food
Drugs
Medical Devices
Radiation-Emitting Products
Vaccines, Blood & Biologics
Animal & Veterinary
Cosmetics
Tobacco Products
New Pediatric Labeling Information Database - Detail
FDA Home
Pediatrics
New Pediatric Labeling Information Database
Detail
-
Please note:
JavaScript must be enabled for this application to work properly.
Check your settings
if you are unsure if your JavaScript is enabled.
Pediatric Labeling Date:
02/06/2015
Trade Name:
Dutrebis
Generic Name or Proper Name (*):
lamivudine and raltegravir
Indications Studied:
Treatment of HIV-1 infection
Label Changes Summary:
*Indicated in adults and pediatric patients 6 - 16 years and weighing at least 30 kg *Should not be used in children below 6 years or in patients weighing less than 30 kg due to weight based dosing requirements in this patient population *Use with caution in pediatric patients with a history of pancreatitis or other significant risk factors for pancreatitis. Discontinue treatment as clinically appropriate *The PK of Dutrebis in the pediatric population has not been studied in clinical trials. Based on modeling and simulation using raltegravir PK data in adults, the PK of raltegravir in Dutrebis in children was projected to result in exposures that have been previously shown to be safe and efficacious in adults *Information on dosing *New drug
Product Labeling:
Labeling
PREA(P):
P
Sponsor:
Merck Sharp & Dohme Corp.
Therapeutic Category:
Antiviral
-
-